Vedtægter for ALK-Abelló A/S

March 27, 2013 09:35 ET | Source: ALK Abello ALK Abello

København, 2013-03-27 14:35 CET (GLOBE NEWSWIRE) -- Vedtægter for ALK-Abelló A/S med seneste ændringer vedtaget på den ordinære generalforsamling den 12. marts 2013.

Attachments

ALK_Vedtægter_12_03_2013 - final.pdf...

Recommended Reading

June 15, 2026 03:00 ET | Source: ALK Abello

EURneffy 1 mg approved in the UK as the first and only needle-free adrenaline treatment for young children (aged 4 and older, 15–30 kg) at risk of anaphylaxis

ALK announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorisation for EURneffy® 1 mg, the first and only needle-free adrenaline treatment for...
Read More
June 11, 2026 03:00 ET | Source: ALK Abello

Anaphylaxis management is falling short in 2026 – EAACI data suggest EURneffy, the only needle-free nasal adrenaline spray, could help close the gap

Over half (54%) of adults at risk of anaphylaxis admit they have been without their adrenaline auto-injector (AAI) when needed—and nearly 40% do not carry one regularly (n=1,238 ).1HCP survey data...
Read More